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TMP/SMX is the mainstay of treatment for nocardiosis. However, there are serious issues of drug resistance 5 and potential side effects like myelosuppression, hepatotoxicity, renal toxicity and significant hypersensitivity reactions with TMP/SMX. 6 Combination with other antibiotics, including amikacin, carbapenems, cephalosporin and fluoroquinolones have been used in patients with disseminated disease. 6 These alternative antibiotics have narrow therapeutic margins and are not active against all nocardia species. 4 Vera-Cabrera et al., 7 for the first time, studied the activity of linezolid against Nocardia spp. in 2001. All clinically significant strains of nocardia were sensitive to linezolid. 7 Moylett et al., 8 in 2003, reported six cases of nocardiosis successfully treated with linezolid. 4 Since 2003, a handful of cases of cerebral nocardiosis treated with linezolid have been published in the literature. Most of them were due to Nocardia farcinica species. 3, [8] [9] [10] Only one case of cerebral Nocardia mexicana with unsuccessful treatment has been reported. 11 We describe the first case of intractable cerebral nocardiosis with Nocardia mexicana that was successfully treated with linezolid after failing multiple anti-nocardial regimens.
A 48-year-old Caucasian male presented in December 2012 with fatigue, dizziness and pancytopenia. Work up revealed acute myeloid leukemia. Following CR after initial induction therapy, the patient received allo-HCT from fully HLA-matched donor sister. Six months after HSCT, the patient developed skin biopsy-proven multi-organ, grade II chronic GvHD. The patient was started on high-dose prednisone and tacrolimus, which improved but did not completely resolve GvHD symptoms. Therefore, the patient was placed on long-term immunosuppression with occasional flares of skin and liver GvHD during his long follow-up course. Sixteen months after GvHD diagnosis, the patient presented with right upper chest discomfort. Chest X-ray ( Figure 1 ) showed a cavitary lesion in the right upper lobe. Sputum and broncho-alveolar lavage (BAL) samples were sent for microbiologic testing. Pulmonary nocardiosis was diagnosed with its characteristic beaded, branching filamentous morphology on Gram stain. Lavage samples were sent for culture, speciation and susceptibility testing. MRI of the brain was negative at the time of initial presentation. The patient was empirically started on trimethoprim/ sulfamethoxazole (TMP/SMX) pending final sensitivity results. However, TMP/SMX had to be replaced by minocycline and amoxicillin-clavulanate as the patient developed hyperkalemia and acute kidney injury.
He continued GvHD immunosuppressive therapy with prednisone and tacrolimus. A month later, final culture and sensitivity report revealed Nocardia mexicana susceptible to ceftriaxone, linezolid and TMP/SMX, while resistant to amikacin, imipenem, amoxicillin-clavulanate, clarithromycin, doxycycline, tobramycin and minocycline. Susceptibility to ciprofloxacin was reported as intermediate and moxifloxacin had a minimum inhibitory concentration (MIC) of 1. Meanwhile, he was readmitted with worsening pneumonia, sepsis and hypotension. Repeat sputum examination was positive for Nocardia. He was again started on TMP/SMX two double-strength (800 mg/160 mg) tablets along with levofloxacin. This time TMP/SMX was discontinued due to worsening pancytopenia. Levofloxacin was replaced by moxifloxacin. Five months later, he was readmitted with left ocular swelling. left orbital swelling and erythema was treated in consultation with ophthalmology as pre-retinal abscess by intraocular vancomycin, ceftazidime, voriconazole followed by amikacin and foscarnet. Brain MRI (Figure 2 ) revealed multiple small intra-cranial lesions in left cerebellum, left occipital, and frontal lobe. Cerebral nocardiosis was suspected. The patient was switched from moxifloxacin to i.v. TMP/SMX 15 mg/kg per day and ceftriaxone. With third time use of TMP/SMX, the patient developed severe pancytopenia, so TMP/SMX was stopped while ceftriaxone continued. Repeat MRI revealed interval enlargement of intra-cranial lesions. Eye swelling and erythema worsened. Patient had to undergo left eye globe enucleation and drainage of orbital abscess. Culture results revealed two colonies of Nocardia most closely related to Nocardia mexicana. TMP/SMX was started for the fourth time and the patient developed nausea, vomiting, hypotension and acute kidney injury. TMP/SMX was once again stopped but this time linezolid 600 mg daily was started.
A month after linezolid was started, follow-up brain MRI showed improving lesions. Antibiotic sensitivity results from intra-ocular sample revealed susceptibility to imipenem, ceftriaxone and linezolid; intermediate susceptibility to minocycline, moxifloxacin and cefepime; and resistance to amikacin, amoxicillin-clavulanate, ciprofloxacin, clarithromycin, doxycycline, tobramycin, and TMP/SMX. A few weeks later, the dose of linezolid was reduced to 300 mg daily, which was continued for 8 weeks. Periodic MRIs showed improvement in the brain lesions. After 2-months of treatment with linezolid, brain MRI showed resolution of lesions. However, the patient developed gradually progressive pancytopenia and peripheral neuropathy. Linezolid was switched to moxifloxacin and i.v. ceftriaxone. Subsequent MRI performed after 6 months of treatment showed no evidence of recurrent or residual disease. The patient eventually was switched to oral antibiotics moxifloxacin and minocycline. Antibiotics were stopped after 1 year of treatment. Serial follow-up brain MRIs revealed no disease recurrence and patient remained asymptomatic. Our patient had multiple risk factors for development of nocardiosis, including diagnosis of AML, allo-HSCT, GvHD, steroids and tacrolimus use. Initially, our patient had a cavitary lung lesion; daunting spectrum of differential diagnosis for cavitary pneumonia includes nocardiosis, mycobacterium tuberculosis and other non-tuberculosis mycobacteria, necrotizing pneumonia, septic emboli, fungal and parasitic infections. Nocardia is a great mimicker, especially of mycobacterium, so its diagnosis requires a high degree of clinical suspicion.
Nocardia mexicana was first identified in 2004 in Mexico by Rodriguez-Nava et al. 12 They found three isolates of nocardia that closely identified Nocardia pseudobransiliensis. After biochemical, taxonomical and molecular study, three isolates were classified as novel species N. mexicana. Susceptibility profiles of the three isolates were identical; high MIC to sulfamethoxazole, amikacin, imipenem, amoxicillin and gentamicin; intermediate MIC to TMP/SMX and ciprofloxacin; low MIC to cefotaxime and ceftriaxone. Since 2004, two cases of Nocardia mexicana have been reported. 11, 13 Reported susceptibility profiles of all these cases were consistent with unusual feature of resistance to multiple antibiotics, including TMP/SMX. Raby et al.
11 reported a case of cerebral Nocardia mexicana with unsuccessful treatment with linezolid. To our knowledge, our patient is the first case of cerebral Nocardia mexicana successfully treated with linezolid. Nocardia mexicana is rare but requires special attention owing to its multidrug resistant property. This fact emphasizes the importance of species identification to guide antibiotic therapy. Cerebral nocardiosis is a serious disease, carrying the highest mortality risk among all bacterial cerebral abscesses.
14 Pulmonary nocardiosis should prompt investigation for disseminated disease. It is important to note that, despite its propensity for hematogenous spread, nocardia is only rarely isolated from blood cultures in disseminated disease. Presence of cerebral lesions in the setting of confirmed pulmonary or skin nocardial infection is strong predictor of cerebral disease. Brain biopsy is generally not mandatory.
Due to paucity of disease, optimal treatment regimens for nocardia have not been established based on large randomized clinical trials. Initial regimen selection should take into account the immune status of the patient, disease severity, comorbidities, dissemination, drug adverse effects or interactions, nocardia species and their antibiotic susceptibility profile. For isolated skin infection, TMP/SMX is the mainstay of empiric treatment. In immunocompromised patients and those with disseminated disease without brain involvement two-drug combination therapy should be preferred (for example, amikacin and TMP-SMX or amikacin, and imipenem or meropenem). Patients with disseminated disease, involving the brain or those with life-threatening infection should be considered for triple combination therapy (for example, TMP-SMX, meropenem or imipenem and amikacin or ceftriaxone in patients with renal failure). In this group, if any of previously mentioned drugs are contraindicated, linezolid is an option as an initial adjunctive therapy. Recommended treatment duration for CNS Nocardiosis is 12 months to prevent disease relapse. 15 Our patient failed multiple antibiotic therapies either due to intolerance or due to resistance. We were reluctant to start linezolid because of its serious and often irreversible side effects, including cytopenia, vision impairment (in the setting of one eye) and peripheral neuropathy. 9 Since nocardiosis is a severe clinical condition, especially in immunocompromised patients with disseminated disease. Risk of developing side effects should be carefully weighed against benefits of starting linezolid therapy.
In conclusion, TMP/SMX-resistant property of N. mexicana in all cases reported up-to-date emphasizes speciation and antibiotic sensitivity testing in every case of nocardiosis. Considering the high mortality associated with cerebral nocardiosis and toxicities of linezolid, the decision to start linezolid therapy should be vigilantly made on individualized basis. Empiric treatment of cerebral nocardiosis should include a multidrug regimen with adequate CNS penetration to prevent development of resistance and relapse. Further antibiotic therapy should be guided by susceptibility results. 
